Carisma Therapeutics, Inc. (NASDAQ:CARM) Receives $4.94 Consensus Target Price from Brokerages

Shares of Carisma Therapeutics, Inc. (NASDAQ:CARM) have earned an average recommendation of “Hold” from the seven research firms that are currently covering the firm, Marketbeat Ratings reports. Five investment analysts have rated the stock with a hold rating, one has given a buy rating and one has issued a strong buy rating on the company. The average 1-year price target among analysts that have updated their coverage on the stock in the last year is $4.94.

A number of equities analysts recently weighed in on CARM shares. Evercore ISI restated an “in-line” rating and issued a $0.70 price objective (down from $4.00) on shares of Carisma Therapeutics in a report on Wednesday, December 11th. D. Boral Capital lowered their price target on Carisma Therapeutics from $24.00 to $12.00 and set a “buy” rating on the stock in a report on Monday, December 9th. Robert W. Baird downgraded Carisma Therapeutics from an “outperform” rating to a “neutral” rating and reduced their price objective for the stock from $10.00 to $1.00 in a report on Thursday, December 12th. EF Hutton Acquisition Co. I upgraded shares of Carisma Therapeutics to a “strong-buy” rating in a research note on Wednesday, October 30th. Finally, HC Wainwright reiterated a “neutral” rating on shares of Carisma Therapeutics in a research note on Monday, December 16th.

Carisma Therapeutics Trading Down 0.6 %

Carisma Therapeutics stock opened at $0.47 on Monday. Carisma Therapeutics has a 12 month low of $0.38 and a 12 month high of $2.94. The company has a market capitalization of $19.67 million, a price-to-earnings ratio of -0.30 and a beta of 1.44. The business’s fifty day simple moving average is $0.69 and its two-hundred day simple moving average is $0.93. The company has a current ratio of 3.23, a quick ratio of 3.23 and a debt-to-equity ratio of 1.39.

Carisma Therapeutics (NASDAQ:CARM) last announced its quarterly earnings results on Thursday, November 7th. The company reported ($0.31) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.31). The company had revenue of $3.39 million for the quarter. Carisma Therapeutics had a negative net margin of 314.78% and a negative return on equity of 957.20%. As a group, equities analysts predict that Carisma Therapeutics will post -1.32 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Carisma Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the stock. Point72 Asia Singapore Pte. Ltd. purchased a new position in Carisma Therapeutics during the second quarter valued at $40,000. Wexford Capital LP lifted its position in shares of Carisma Therapeutics by 75.5% during the 3rd quarter. Wexford Capital LP now owns 34,861 shares of the company’s stock valued at $34,000 after buying an additional 15,000 shares in the last quarter. Finally, Barclays PLC grew its stake in shares of Carisma Therapeutics by 3,661,933.3% during the 3rd quarter. Barclays PLC now owns 549,305 shares of the company’s stock valued at $539,000 after acquiring an additional 549,290 shares during the period. 44.27% of the stock is currently owned by hedge funds and other institutional investors.

About Carisma Therapeutics

Carisma Therapeutics, Inc, a clinical-stage cell therapy company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases in the United States. The company's ex vivo CAR-M cell therapies include CT-0508, a CAR-macrophage, which is in Phase 1 clinical trial to treat solid tumors; CT-0525, a CAR-monocyte that is in Phase 1 clinical trial to treat solid tumors; and CT-1119, a mesothelin-targeted CAR-Monocyte that is in pre-clinical stage to treat patients with advanced mesothelin-positive solid tumors, including lung cancer, mesothelioma, pancreatic cancer, ovarian cancer, and others.